Filing Details
- Accession Number:
- 0001209191-17-047430
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-03 17:06:51
- Reporting Period:
- 2017-08-01
- Filing Date:
- 2017-08-03
- Accepted Time:
- 2017-08-03 17:06:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1437786 | Immune Design Corp. | IMDZ | Pharmaceutical Preparations (2834) | 262007174 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1605922 | Wayne Gombotz | C/O Immune Design Corp. 1616 Eastlake Ave. E., Suite 310 Seattle WA 98102 | Chief Development Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-08-01 | 10,000 | $1.31 | 33,054 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-08-01 | 9,253 | $11.40 | 23,801 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-08-01 | 747 | $11.80 | 23,054 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Rt to Buy) | Disposition | 2017-08-01 | 10,000 | $0.00 | 10,000 | $1.31 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 38,715 | 2021-12-08 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 7, 2017.
- The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $10.70 to $11.65 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $11.70 to $11.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
- Fully vested and immediately exercisable.
Billionaire Hedge Funds
